Galectin Therapeutics Inc (GALT) - Total Liabilities
Based on the latest financial reports, Galectin Therapeutics Inc (GALT) has total liabilities worth $138.17 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Galectin Therapeutics Inc cash conversion from operations to assess how effectively this company generates cash.
Galectin Therapeutics Inc - Total Liabilities Trend (2000–2024)
This chart illustrates how Galectin Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check GALT cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Galectin Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Galectin Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aurum Resources Ltd
AU:AUE
|
Australia | AU$3.30 Million |
|
Unic Technology
TWO:5452
|
Taiwan | NT$1.64 Billion |
|
Resources Connection Inc
NASDAQ:RGP
|
USA | $94.69 Million |
|
Kian Shen Corp
TW:1525
|
Taiwan | NT$809.83 Million |
|
CF Bankshares Inc
NASDAQ:CFBK
|
USA | $1.61 Billion |
|
D O Green Technologies Bhd
KLSE:7204
|
Malaysia | RM811.73 Million |
|
Element 29 Resources Inc
V:ECU
|
Canada | CA$251.45K |
|
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.
IS:ONCSM
|
Turkey | TL120.48 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Galectin Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Galectin Therapeutics Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 10.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galectin Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galectin Therapeutics Inc (2000–2024)
The table below shows the annual total liabilities of Galectin Therapeutics Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $120.56 Million | +36.32% |
| 2023-12-31 | $88.44 Million | +65.38% |
| 2022-12-31 | $53.48 Million | +36.39% |
| 2021-12-31 | $39.21 Million | +625.19% |
| 2020-12-31 | $5.41 Million | +88.27% |
| 2019-12-31 | $2.87 Million | +36.24% |
| 2018-12-31 | $2.11 Million | -28.98% |
| 2017-12-31 | $2.97 Million | -21.48% |
| 2016-12-31 | $3.78 Million | +177.94% |
| 2015-12-31 | $1.36 Million | -20.14% |
| 2014-12-31 | $1.70 Million | -31.50% |
| 2013-12-31 | $2.49 Million | +51.22% |
| 2012-12-31 | $1.64 Million | -25.78% |
| 2011-12-31 | $2.21 Million | -72.29% |
| 2010-12-31 | $7.99 Million | +63.04% |
| 2009-12-31 | $4.90 Million | +317.99% |
| 2008-12-31 | $1.17 Million | -75.07% |
| 2007-12-31 | $4.71 Million | -26.30% |
| 2006-12-31 | $6.38 Million | +362.68% |
| 2005-12-31 | $1.38 Million | +37.31% |
| 2004-12-31 | $1.00 Million | +165.94% |
| 2003-12-31 | $377.91K | -43.32% |
| 2002-12-31 | $666.79K | +21.08% |
| 2001-12-31 | $550.70K | +205.95% |
| 2000-12-31 | $180.00K | -- |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 cl… Read more